AIDXNasdaqServices-Testing LaboratoriesFiscal year ends December 31
20/20 Biolabs, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.26−0.00 (-0.12%)
Close on Oct 19, 2026
- Market cap
- $2.81M
- P/E (TTM)
- –
- Dividend yield
- –
20/20 Biolabs, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q2 25 | Q1 25 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| OneTest [Member] | $695.95K | $310.10K | $473.17K | $471.38K | 95.3% | +47.1% |
| BioCheck [Member] | $34.62K | $21.55K | $40.87K | $56.97K | 4.7% | -15.3% |
| CLIAx [Member] | $0 | $21.73K | $21.02K | $25.47K | 0.0% | -100.0% |
By region
From the segment and revenue-disaggregation notes of 20/20 Biolabs's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.